NovaBay Pharmaceuticals Reports Positive Data From Exploratory Phase 2 Trial
Multi-Center Study Planned in Q3 for Lead Anti-Infective, NVC-422, in Urinary Catheter Blockage and Encrustation
EMERYVILLE, Calif., April 15, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
Certain Gram-negative pathogens present in bacteriuria can cause urinary catheter blockage, a common occurrence among patients who are permanently catheterized. Urinary catheter blockage can often lead to catheter-associated urinary tract infections (CAUTI). Permanently catheterized patients include those suffering from conditions such as spinal cord injury, neurogenic bladder, spina bifida and multiple sclerosis.
"We are encouraged by the results of this study, both in terms of treatment tolerability and the activity against multiple uropathogens in patients with high levels of bacteriuria," said Dr. Behzad Khosrovi, senior vice president of product development. "We now look forward to initiating additional studies evaluating the use of advanced formulations of NVC-422 in preventing or reducing urinary catheter blockage and encrustation in permanently catheterized spinal cord injury patients."
Study Design and Results
Enrollment criteria included a condition requiring chronic transurethral catheterization for at least one month prior to enrollment, documented high levels of bacteriuria, and no treatment with antimicrobial agents during the preceding week. Following baseline urine cultures, 25 to 100mL of a sterile solution of NVC-422, depending on bladder capacity, was instilled through the catheter into the bladder. The drainage tube was clamped for 1 hour and then allowed to drain. Urine specimens were collected before and following each instillation and daily during post-treatment follow-up.
In the first part of the study, five patients were treated with a single administration of 0.1% NVC-422. The treatment was well tolerated and some transient antimicrobial activity was observed. In Part 2a of the study, five patients were treated with 0.1% NVC-422 daily for seven days; in Part 2b, five patients were treated with a higher NVC-422 concentration of 0.2% daily for seven days. No significant adverse events related to NVC-422 were observed.
Despite the presence of high urinary concentrations (greater than 100,000 colony-forming units per mL) of multiple uropathogens at baseline, a number of these were eradicated by the end of the treatment. These effects were more pronounced in subjects treated with the higher concentration of NVC-422.
NovaBay's lead Aganocide(R) compound, NVC-422, has broad-spectrum anti-microbial activity against bacteria tested, including uropathogens, bacteria resistant to antibiotics, and bacteria encased in biofilm. The use of NVC-422 solutions to control bacteria that inevitably and rapidly develop in urinary catheters and in the bladder represents a significant opportunity for NovaBay. These bacteria are increasingly resistant to antibiotics.
"The encouraging findings of this exploratory study lay the foundation for future investigation of the potential role of this class of non-antibiotic antimicrobials in controlling the consequences of catheter-associated bacteriuria," said Dr. Rabih O. Darouiche, the principal investigator of the study and a professor and director of the Center for Prostheses Infection at Baylor College of Medicine.
CAUTI is the most common type of hospital-acquired infection accounting for approximately 30 percent of such infections and for most of the 900,000 patients with bacteriuria in U.S. hospitals annually.
NovaBay plans to initiate a multi-center Phase 2 trial of NVC-422 in the third quarter for the treatment of urinary catheter blockage and encrustation.
Conference Call Scheduled
On Monday, April 19, at 2 p.m. EDT, members of NovaBay's management team will host a conference call to discuss results of the trial and to provide a pipeline update of its development programs. To join the audio conference and participate in the Q&A session, please call 1-800-434-1335 (outside the U.S., dial 1-404-920-6442), and provide the operator with code 353316.
Live audio of the conference call will be broadcast simultaneously over the internet. Please pre-register for the call at: http://tinyurl.com/novapharmreg. Once the registration process is complete, you will receive a confirmation e-mail with instructions on how to join the conference.
A replay of the webcast will be available shortly after the call and may be accessed via NovaBay's website: www.novabaypharma.com.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biotechnology company
focused on developing its proprietary and patented Aganocide(R)
compounds, which are novel, synthetic anti-infective product candidates
with equivalent activity to the active antimicrobial molecules
generated within white blood cells. NovaBay's Aganocide compounds are
being developed to treat and prevent a wide range of infections without
causing bacterial resistance. NovaBay has internal development programs
aimed at addressing hospital and respiratory infections. The company
has a license and research collaboration agreement with Alcon, Inc. for
use of NovaBay's Aganocide compounds to treat eye, ear and sinus
infections as well as for contact lens care. NovaBay has also entered
into an agreement with Galderma S.A. to develop and commercialize
NovaBay's Aganocide compounds in acne, impetigo and other
dermatological indications. For more information visit
Cautionary Information Regarding Forward-Looking Statements
This release contains forward-looking statements, which are based upon
management's current expectations, assumptions, estimates, projections
and beliefs. Statements regarding NovaBay's expectations for conducting
additional clinical trials of NVC-422 for the treatment of urinary
catheter blockage and encrustation, and that the use of NVC-422
solutions to control bacteria that inevitably and rapidly develop in
urinary catheters and in the bladder represents a significant
opportunity for NovaBay, as well as other statements that relate to
future events or results, are forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those
expressed in or implied by the forward-looking statements. Factors that
might cause or contribute to such differences include, but are not
limited to: the risk that NovaBay may experience unexpected results in
further studies which may limit, delay or prevent NovaBay from
conducting further clinical trials; unexpected adverse side effects or
inadequate therapeutic efficacy of NVC-422 may inhibit NVC-422 from
becoming a treatment for these types of infections; and the risk of
unexpected delays in the regulatory process which may delay the
commencement or completion of clinical trials. Other risks relating to
NovaBay and its Aganocide compounds, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay's Annual Report on Form 10-K for the period ended December 31,
2009, under the caption "Risk Factors" in Item 1A of Part I of that
report, filed with the Securities and Exchange Commission on March 29,
2010. The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise or
update publicly any forward-looking statement except as required by
CONTACT: NovaBay Pharmaceuticals, Inc.
Tom Paulson, Chief Financial Officer
Susan Thomas, Director of Corporate Communications